Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1740027
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1740027
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region
PUBLISHED:
PAGES: 457 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is estimated to be valued at USD 880.3 Mn in 2025 and is expected to reach USD 1,178.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.25% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 880.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 4.25% | 2032 Value Projection: | USD 1,178.0 Mn |
Ornithine transcarbamylase (OTC) deficiency is a genetic disorder that causes excessive ammonia buildup in the blood (hyperammonemia). When ammonia levels are too high, it is toxic and affects the nervous system. This signs and symptoms may also include lack of energy and appetite, an uncontrollable breathing rate, body temperature, unusual body movements, seizures, or coma. This form can be found in both males and females. OTC is caused by genetic changes in the OTC gene, and it is inherited in an X-linked manner. Complications from ornithine transcarbamylase deficiency may include developmental delay and intellectual disability. Progressive liver damage may also occur.
Market Dynamics
Increasing inorganic growth strategies by market players is expected to drive the market growth over the forecast period. For instance, in September 2022, GENFIT, a late-stage biopharmaceutical company, announced it had entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, is a clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. This agreement significantly expands GENFIT's pipeline with VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD).
Increasing product launches by key players for ornithine transcarbamylase (OTC) deficiency treatment is expected to drive the market growth over the forecast period. For instance, in September 2022, Medunik USA, a pharmaceutical company, announced the launch of Pheburane oral pellets, a unique taste-masked formulation of sodium phenylbutyrate (NaPB). Pheburane is a prescription medicine, used along with a specific diet, for the long-term management of adults and children with urea cycle disorders (UCDs).
Key features of the study:
- This report provides in-depth analysis of the global ornithine transcarbamylase (OTC) deficiency treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ornithine transcarbamylase (OTC) deficiency market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Horizon Therapeutics Plc, Bausch Health Companies Inc., Danone, Nestle, Ultragenyx Pharmaceutical., Arcturus Therapeutics, Inc. , Abbott., Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., Assertio Holdings, Inc., iECURE, and Translate Bio, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ornithine transcarbamylase (OTC) deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ornithine transcarbamylase (OTC) deficiency treatment market.
Detailed Segmentation:
- Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Drug Type:
- Buphenyl
- Ravicti
- Ammonul
- Others
- Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Route of Administration:
- Oral
- Intravenous
- Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Horizon Therapeutics Plc.
- Bausch Health Companies Inc
- Danone
- Nestle
- Ultragenyx Pharmaceutical
- Arcturus Therapeutics, Inc
- Abbott
- Swedish Orphan Biovitrum AB
- Acer Therapeutics Inc
- Assertio Holdings, Inc
- iECURE
- Translate Bio, Inc.
Product Code: CMI5514
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Pipeline Analysis
4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- COVID-19 Impact on the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market
5. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Drug Type, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Buphenyl
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Ravicti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Ammonul
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Route of Administration, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Distribution Channel, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
8. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Region, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2020-2032,(US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2020-2032,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2020-2032,(US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2020-2032,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2020-2032,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Competitive Snapshot
- Heat Map Analysis
- Market Share Analysis
- Horizon Therapeutics Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Danone
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Nestle
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ultragenyx Pharmaceutical.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Arcturus Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Swedish Orphan Biovitrum AB
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Acer Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Assertio Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- iECURE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Translate Bio, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- StrategiesA
- Horizon Therapeutics Plc
10. Section
- Research Methodology
- About us
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.